Related Experiment Video

Updated: Aug 12, 2026

Cervical Heterotopic Mouse Heart Transplantation using End-to-side Anastomosis Technique to Study Transplant Immunology
08:15

Cervical Heterotopic Mouse Heart Transplantation using End-to-side Anastomosis Technique to Study Transplant Immunology

Published on: July 3, 2026

First Successful Cardiac Myosin Inhibitor Use for Donor-Derived HCM After Heart Transplant

Hossam Albeyoumi Mohammed1, Ashwin Pillai2, Andrew Scatola3

  • 1Internal Medicine, University of Connecticut, Farmington, Connecticut, USA.

JACC. Case Reports
|August 11, 2026
PubMed
Summary

Donor-derived hypertrophic cardiomyopathy (HCM) is rare but treatable. Mavacamten effectively reduced obstruction and improved function in a heart transplant patient, showing promise for early intervention.

Keywords:
cardiac transplantcardiomyopathypostoperative

More Related Videos

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model06:45

A Modified Cuff Technique for Mouse Cervical Heterotopic Heart Transplantation Model

Published on: February 7, 2022

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples14:39

Isolation and Functional Characterization of Human Ventricular Cardiomyocytes from Fresh Surgical Samples

Published on: April 21, 2014

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...